The Times Australia
Fisher and Paykel Appliances
The Times World News

.

We have drugs to manage HIV. So why are we spending millions looking for cures?

  • Written by Bridget Haire, Associate Professor, Public Health Ethics, School of Population Health, UNSW Sydney

Over the past three decades there have been amazing advances in treating and preventing HIV.

It’s now a manageable infection. A person with HIV who takes HIV medicine consistently, before their immune system declines, can expect to live almost as long as someone without HIV[1].

The same drugs prevent transmission[2] of the virus to sexual partners.

There is still no effective HIV vaccine[3]. But there are highly effective drugs[4] to prevent HIV infection for people without HIV who are at higher risk of acquiring it.

These drugs are known as as “pre-exposure prophylaxis” or PrEP[5]. These come as a pill, which needs to be taken either daily, or “on demand[6]” before and after risky sex. An injection[7] that protects against HIV for six months has recently been approved in the United States[8].

So with such effective HIV treatment and PrEP, why are we still spending millions[9] looking for HIV cures?

Not everyone has access to these drugs

Access to HIV drugs and PrEP depends on the availability of health clinics, health professionals, and the means to supply and distribute the drugs. In some countries, this infrastructure may not be secure.

For instance, earlier this year, US President Donald Trump’s dissolution of the USAID foreign aid program[10] has threatened the delivery of HIV drugs to many low-income countries.

This demonstrates the fragility of current approaches to treatment and prevention. A secure, uninterrupted supply of HIV medicine is required, and without this, lives will be lost and the number of new cases of HIV[11] will rise.

Another example is the six-monthly PrEP injection just approved in the US. This drug has great potential for controlling HIV if it is made available and affordable in countries with the greatest HIV burden.

But the prospect for lower-income countries accessing this expensive drug looks uncertain, even if it can be made at a fraction of its current cost, as some researchers say[12].

So despite the success of HIV drugs and PrEP, precarious health-care systems and high drug costs mean we can’t rely on them to bring an end to the ongoing global HIV pandemic. That’s why we also still need to look at other options.

Haven’t people already been ‘cured’?

Worldwide, at least[13] seven people[14] have been “cured” of HIV – or at least have had long-term sustained remission. This means that after stopping HIV drugs, they did not have any replicating HIV in their blood for months or years.

In each case, the person with HIV also had a life-threatening cancer needing a bone marrow transplant. They were each matched with a donor who had a specific genetic variation that resulted in not having HIV receptors in key bone marrow cells.

After the bone marrow transplant, recipients stopped HIV drugs, without detectable levels of the virus returning. The new immune cells made in the transplanted bone marrow lacked the HIV receptors. This stopped the virus from infecting cells and replicating.

But this genetic variation is very rare[15]. Bone marrow transplantation is also risky and extremely resource-intensive[16]. So while this strategy has worked for a few people, it is not a scalable prospect for curing HIV more widely.

So we need to keep looking for other options for a cure, including basic laboratory research to get us there.

How about the ‘breakthrough’ I’ve heard about?

HIV treatment stops the HIV replication that causes immune damage. But there are places in the body where the virus “hides” and drugs cannot reach. If the drugs are stopped, the “latent” HIV comes out of hiding and replicates again. So it can damage the immune system, leading to HIV-related disease.

One approach is to try to force the hidden or latent HIV out into the open, so drugs can target it. This is a strategy called “shock and kill”. And an example of such Australian research was recently reported in the media as a “breakthrough[17]” in the search for an HIV cure.

Researchers in Melbourne have developed a lipid nanoparticle – a tiny ball of fat – that encapsulates messenger RNA (or mRNA) and delivers a “message” to infected white blood cells. This prompts the cells to reveal[18] the “hiding” HIV.

In theory, this will allow the immune system or HIV drugs to target the virus.

This discovery is an important step. However, it is still in the laboratory phase of testing, and is just one piece of the puzzle.

We could say the same about many other results[19] heralded as moving closer to a cure for HIV[20].

Further research on safety and efficacy is needed before testing in human clinical trials. Such trials start with small numbers and the trialling process takes many years. This and other steps towards a cure are slow and expensive, but necessary.

Importantly, any cure would ultimately need to be fairly low-tech to deliver for it to be feasible and affordable in low-income countries globally[21].

So where does that leave us?

A cure for HIV[22] that is affordable and scalable would have a profound impact on human heath globally, particularly for people living with HIV[23]. To get there is a long and arduous path that involves solving a range of scientific puzzles, followed by addressing implementation challenges.

In the meantime, ensuring people at risk of HIV have access to testing and prevention interventions – such as PrEP and safe injecting equipment – remains crucial. People living with HIV also need sustained access to effective treatment – regardless of where they live.

References

  1. ^ as long as someone without HIV (www.thelancet.com)
  2. ^ prevent transmission (www.aidsmap.com)
  3. ^ no effective HIV vaccine (www.sciencenews.org)
  4. ^ highly effective drugs (theconversation.com)
  5. ^ PrEP (endinghiv.org.au)
  6. ^ on demand (endinghiv.org.au)
  7. ^ An injection (www.nytimes.com)
  8. ^ in the United States (www.nbcnews.com)
  9. ^ spending millions (www.genengnews.com)
  10. ^ the USAID foreign aid program (www.kff.org)
  11. ^ new cases of HIV (msf.org.au)
  12. ^ as some researchers say (www.theguardian.com)
  13. ^ at least (www.healio.com)
  14. ^ seven people (www.nature.com)
  15. ^ is very rare (www.tandfonline.com)
  16. ^ risky and extremely resource-intensive (pmc.ncbi.nlm.nih.gov)
  17. ^ breakthrough (www.theguardian.com)
  18. ^ reveal (www.nature.com)
  19. ^ many other results (www.aidsmap.com)
  20. ^ closer to a cure for HIV (newsroom.uvahealth.com)
  21. ^ low-income countries globally (pmc.ncbi.nlm.nih.gov)
  22. ^ cure for HIV (hivcure.com.au)
  23. ^ particularly for people living with HIV (napwha.org.au)

Read more https://theconversation.com/we-have-drugs-to-manage-hiv-so-why-are-we-spending-millions-looking-for-cures-258391

Times Magazine

Can bigger-is-better ‘scaling laws’ keep AI improving forever? History says we can’t be too sure

OpenAI chief executive Sam Altman – perhaps the most prominent face of the artificial intellig...

A backlash against AI imagery in ads may have begun as brands promote ‘human-made’

In a wave of new ads, brands like Heineken, Polaroid and Cadbury have started hating on artifici...

Home batteries now four times the size as new installers enter the market

Australians are investing in larger home battery set ups than ever before with data showing the ...

Q&A with Freya Alexander – the young artist transforming co-working spaces into creative galleries

As the current Artist in Residence at Hub Australia, Freya Alexander is bringing colour and creativi...

This Christmas, Give the Navman Gift That Never Stops Giving – Safety

Protect your loved one’s drives with a Navman Dash Cam.  This Christmas don’t just give – prote...

Yoto now available in Kmart and The Memo, bringing screen-free storytelling to Australian families

Yoto, the kids’ audio platform inspiring creativity and imagination around the world, has launched i...

The Times Features

Why the Mortgage Industry Needs More Women (And What We're Actually Doing About It)

I've been in fintech and the mortgage industry for about a year and a half now. My background is i...

Inflation jumps in October, adding to pressure on government to make budget savings

Annual inflation rose[1] to a 16-month high of 3.8% in October, adding to pressure on the govern...

Transforming Addiction Treatment Marketing Across Australasia & Southeast Asia

In a competitive and highly regulated space like addiction treatment, standing out online is no sm...

Aiper Scuba X1 Robotic Pool Cleaner Review: Powerful Cleaning, Smart Design

If you’re anything like me, the dream is a pool that always looks swimmable without you having to ha...

YepAI Emerges as AI Dark Horse, Launches V3 SuperAgent to Revolutionize E-commerce

November 24, 2025 – YepAI today announced the launch of its V3 SuperAgent, an enhanced AI platf...

What SMEs Should Look For When Choosing a Shared Office in 2026

Small and medium-sized enterprises remain the backbone of Australia’s economy. As of mid-2024, sma...

Anthony Albanese Probably Won’t Lead Labor Into the Next Federal Election — So Who Will?

As Australia edges closer to the next federal election, a quiet but unmistakable shift is rippli...

Top doctors tip into AI medtech capital raise a second time as Aussie start up expands globally

Medow Health AI, an Australian start up developing AI native tools for specialist doctors to  auto...

Record-breaking prize home draw offers Aussies a shot at luxury living

With home ownership slipping out of reach for many Australians, a growing number are snapping up...